The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.
 
Whitley Hatton
No Relationships to Disclose
 
Arnab Basu
No Relationships to Disclose
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Sanofi
Speakers' Bureau - Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Ellen Jaeger
No Relationships to Disclose
 
Elisa Marie Ledet
No Relationships to Disclose
 
Patrick Cotogno
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst); Sotio (Inst)
 
Charlotte Manogue
No Relationships to Disclose
 
Brian E. Lewis
No Relationships to Disclose
 
Jodi Lyn Layton
No Relationships to Disclose
 
Spencer Krane
No Relationships to Disclose
 
Oliver A. Sartor
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Arpita Desai
No Relationships to Disclose
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)